Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The Influence of Time-Limited Immunity on a COVID-19 Epidemic: A Simulation Study

Robert J. Kosinski
doi: https://doi.org/10.1101/2020.06.28.20142141
Robert J. Kosinski
Professor Emeritus of Biological Sciences, Clemson University,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rjksn@clemson.edu rjksn@clemson.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

A series of spreadsheet simulations using SEIS, SEIR, and SEIRS models showed that different durations of effective immunity could have important consequences for the prevalence of an epidemic disease with COVID-19 characteristics. Immunity that lasted four weeks, twelve weeks, six months, one year, and two years was tested with pathogen R0 values of 1.5, 2.3, and 3.0. Shorter durations of immunity resulted in oscillations in disease prevalence. Immunity that lasted from three months to two years produced recurrent disease outbreaks triggered by the expiration of immunity. If immunity “faded out” gradually instead of persisting at full effectiveness to the end of the immune period, the recurrent outbreaks became more frequent. The duration of effective immunity is an important consideration in the epidemiology of a disease like COVID-19.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The study required no funding. It's a simulation study only.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This is a simulation study only. There are no human subjects, and no IRB approval should be necessary.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The MS is complete as it is. There are no extra data files

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted June 29, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The Influence of Time-Limited Immunity on a COVID-19 Epidemic: A Simulation Study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The Influence of Time-Limited Immunity on a COVID-19 Epidemic: A Simulation Study
Robert J. Kosinski
medRxiv 2020.06.28.20142141; doi: https://doi.org/10.1101/2020.06.28.20142141
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
The Influence of Time-Limited Immunity on a COVID-19 Epidemic: A Simulation Study
Robert J. Kosinski
medRxiv 2020.06.28.20142141; doi: https://doi.org/10.1101/2020.06.28.20142141

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (434)
  • Anesthesia (99)
  • Cardiovascular Medicine (949)
  • Dentistry and Oral Medicine (178)
  • Dermatology (111)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (422)
  • Epidemiology (8997)
  • Forensic Medicine (4)
  • Gastroenterology (421)
  • Genetic and Genomic Medicine (1960)
  • Geriatric Medicine (191)
  • Health Economics (403)
  • Health Informatics (1330)
  • Health Policy (661)
  • Health Systems and Quality Improvement (520)
  • Hematology (212)
  • HIV/AIDS (420)
  • Infectious Diseases (except HIV/AIDS) (10820)
  • Intensive Care and Critical Care Medicine (575)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (222)
  • Neurology (1834)
  • Nursing (110)
  • Nutrition (274)
  • Obstetrics and Gynecology (356)
  • Occupational and Environmental Health (470)
  • Oncology (1000)
  • Ophthalmology (299)
  • Orthopedics (111)
  • Otolaryngology (183)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (581)
  • Pharmacology and Therapeutics (276)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1907)
  • Public and Global Health (4127)
  • Radiology and Imaging (676)
  • Rehabilitation Medicine and Physical Therapy (368)
  • Respiratory Medicine (550)
  • Rheumatology (226)
  • Sexual and Reproductive Health (191)
  • Sports Medicine (178)
  • Surgery (207)
  • Toxicology (39)
  • Transplantation (109)
  • Urology (82)